Free shipping on all orders over $ 500

Alofanib (RPT835)

Cat. No. M10590
Alofanib (RPT835) Structure
Synonym:

RPT835

Size Price Availability Quantity
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
  • Current batch:
  • Purity >98.5%
  • COA
  • MSDS
Biological Activity

Alofanib (RPT835) is a novel selective allosteric inhibitor of FGFR2 and has a dramatic inhibitory effect with IC50 <10 nM on FGF2-induced phoshphorylation of FRS2a in KATO III cells. Alofanib induces mainly apoptosis with cleavage of caspase 3, PARP and Bcl-2 in SKOV3 cell line. Cytotoxic effect of compound on ovarian cancer cells is low. Alofanib inhibits phosphorylation of FRS2α with the IC50 values of 7 and 9 nmol/l in cancer cells expressing different FGFR2 isoforms. In a panel of four cell lines representing several tumour types (triple-negative breast cancer,melanoma, and ovarian cancer), alofanib inhibits FGF-mediated proliferation with 50% growth inhibition (GI50) values of 16-370 nmol/l. Alofanib dose dependently inhibits the proliferation and migration of human and mouse endothelial cells (GI50: 11-58 nmol/l) compared with brivanib and bevacizumab. 

In vivo, Intravenous alofanib significantly in dose-dependent manner potentiated the efficiency of the combination of paclitaxel and carboplatin. Alofanib suppresses angiogenesis in ovarian cancer mouse model. In a FGFR-driven human tumour xenograft model, oral administration of alofanib is well tolerated and results in potent antitumour activity.

Protocol
Cell Experiment
Cell lines SKOV3, HS478T, Mel Kor cells
Preparation method Inhibited growth of SKOV3 and HS578T cells with GI50s of 0.37 and 0.21 μM. Did not potently inhibit growth of Mel Kor cells that do not contain FGFR2 (GI50>10 μM).
Concentrations 0.2, 0.4, 0.8 μM
Incubation time 6 hours after dosing, FGF2 is added at a concentration of 25 ng/ml
Animal Experiment
Animal models C57Bl/6 × DBA/2 F1 mice of 22-30 g
Formulation vehicle (water)
Dosages 10 mg/kg/d
Administration Intraperitoneally, 0, 3 and 6 d
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

Chemical Information
Molecular Weight 413.40
Formula C19H15N3O6S
CAS Number 1612888-66-0
Purity >98.5%
Solubility DMSO ≥ 30 mg/mL
Storage at -20°C
References

[1] Alexandra Tyulyandina, et al. Invest New Drugs. Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies

[2] Ilya Tsimafeyeu, et al. Eur J Cancer. Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumour models

[3] D A Khochenkov, et al. Bull Exp Biol Med. Antiangiogenic Activity of Alofanib, an Allosteric Inhibitor of Fibroblast Growth Factor Receptor 2

Related FGFR Products
EOC317

EOC317 (ACTB-1003) is an orally available kinase inhibitor that inhibits FGFR1, VEGFR2, and tie-2 with IC50 values of 6,2, and 4 nM, respectively.

PRN1371

PRN1371 is a highly selective and potent inhibitor of FGFR1-4 and CSF1R against FGFR1, FGFR2, FGFR3, FGFR4 and CSF1R IC50 The values are 0.6, 1.3, 4.1, 19.3, and 8.1 nM, respectively.

ASP5878

ASP5878 is a novel selective FGFR inhibitor with IC50 values of 0.47 nM, 0.6 nM, 0.74 nM and 3.5 nM for FGFR 1, 2, 3 and 4, respectively.

PF-05231023

PF-05231023 is an FGF21-receptor agonist, it is also a potential treatment for T2DM.

Futibatinib (TAS-120)

Futibatinib (TAS-120) is an oral bioavailable, highly selective and irreversible FGFR inhibitor with IC50 of 3.9, 1.3, 1.6 and 8.3 nM against the four FGFR 1-4 subtypes, respectively. Futibatinib inhibited mutant and wild-type FGFR2 with IC50 similarity (wild-type FGFR2=0.9 nM; V5651 = 1 to 3 nM; N550H = 3.6 nM. E566G = 2.4 nM).

  Catalog
Abmole Inhibitor Catalog




Keywords: Alofanib (RPT835), RPT835 supplier, FGFR, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.